The effect of molnupiravir capsules (molnupiravir) in treating COVID-19

Molnupiravir capsules (Molnupiravir) is a drug used to treat COVID-19, but its effectiveness is still being evaluated in clinical studies. Here are some summaries on the effectiveness of monogravir capsules in treating COVID-19 infections:

1.Reducing the risk of hospitalization: Early clinical trials have shown that monogravir capsules can significantly reduce the risk of hospitalization for COVID-19 infected patients when used early. This is a positive sign for reducing the burden on the healthcare system and providing more treatment options.

2.Reducing symptoms: Research on monogravir capsules also shows that it can reduce symptoms in COVID-19 patients, including fever, cough, fatigue, etc. This can improve the patient's quality of life and reduce the discomfort of the disease.

3.Reducing the spread of the virus: By reducing the amount of virus in the patient's body, monogravir capsules are expected to reduce the patient's risk of infection to others and help control the spread of the epidemic.

However, it is important to note that the safety and effectiveness of monogravir capsules are still being continuously evaluated in studies. In addition, the effectiveness of the drug may vary based on factors such as individual differences, virus variants, and duration of medication.

Therefore, patients should follow the advice of their medical professional and assess whether monogravir capsules are appropriate for their specific situation. In addition, the medical community will continue to monitor the effects of monogravir capsules and conduct further research to fully understand its potential benefits in the treatment of COVID-19. Therefore, it is important to stay up to date on the latest guidance from your local health department and the results of clinical trials.

Monolavir capsules are already on the market in China, but are not yet included in medical insurance. Please consult your local hospital pharmacy for specific prices. The cheaper ones abroad are Indian generic drugs, which cost around three to four hundred yuan, and the ingredients of domestic original drugs and foreign generic drugs are basically the same.